Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

Stimulating either of a pair of crucial nerves that carry messages from the brain to several major organs could be an ...

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures ...

Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

The study observed that self-reflection and positive approach can help in improving the symptoms of depression ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

The treatment of mood disorders and chronic pain conditions is a difficult undertaking. If you’ve already explored various ...

Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Launched this year, Miami-based Hope Therapeutics is a developer of NRX-100, a ketamine drug used to treat suicidal ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...